TARGETING EXHAUSTED CYTOTOXIC T CELLS BY CTLA-4 BLOCKADE PROMOTES ELIMINATION OF NEOPLASTIC CELLS IN HUMAN MYELOFIBROSIS XENOGRAFTS

EHA Library, Lara Tavernari, 419087

THE EFFECT OF METHYLATION ON THE LET-7-BCL-XL-BCL2 AXIS AND THE POTENTIAL USE OF BH3 MIMETIC DRUGS IN HISTIOCYTIC NEOPLASMS

EHA Library, Oshrat Hershkovitz-Rokah, 419088

EFFICACY OF INCA033989 IN CHRONIC AND ADVANCED FORMS OF CALRDEL52 AND CALRINS5 MYELOPROLIFERATIVE NEOPLASMS (MPN) MODELS

EHA Library, Isabelle Plo, 419089

THE ATYPICAL CHEMOKINE RECEPTOR CCRL2 IS UPREGULATED AND PROMOTES INTERFERON-GAMMA SIGNALING IN ADVANCED MYELOPROLIFERATIVE NEOPLASMS.

EHA Library, Theodora Chatzilygeroudi, 419090

UMBILICAL CORD MESENCHYMAL STROMAL CELLS AMELIORATE MYELOFIBROSIS IN VIVO.

EHA Library, Chien-Chin Lin, 419091

TAGRAXOFUSP EXHIBITS ANTITUMORAL ACTIVITY IN PRECLINICAL MODELS OF MYELOFIBROSIS AND ENHANCES ANTILEUKEMIC ACTIVITY OF JAK INHIBITORS

EHA Library, Vittoria Nicolis di Robilant, 419092

ADVANCING EARLY DETECTION AND IMPROVED TARGETED THERAPY IN MYELOPROLIFERATIVE NEOPLASMS: INSIGHTS FROM MULTIMODAL IMAGING AND NANOPARTICLE-MEDIATED DRUG DELIVERY

EHA Library, Julian Baumeister, 419093

SINGLE CELL MULTIOMICS IDENTIFIES ABERRANT COMMUNICATION BETWEEN DENDRITIC CELLS AND LEUKAEMIA STEM CELLS AS A THERAPEUTICALLY TARGETABLE AXIS IN JUVENILE MYELOMONOCYTIC LEUKAEMIA

EHA Library, Eleni Louka, 419094

TARGETED T CELLS AGAINST HEMATOPOIETIC CELLS EXPRESSING ONCOGENIC CALRETICULIN MUTANTS

EHA Library, Robert Kralovics, 419095

TET2 ADDITIONAL MUTATIONS AT DIAGNOSIS IMPACT THE RESPONSE OF FIRST-LINE TREATMENT WITH HYDROXYUREA OR INTERFERON-Α IN ESSENTIAL THROMBOCYTHEMIA

EHA Library, Carole Mosnier, 419096

ESTABLISHMENT OF A NOVEL PRECLINICAL MOUSE MODEL FOR ADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Martina Konantz, 419097

IMPACT OF GENETIC BACKGROUND ON THE FIBROTIC TRANSFORMATION IN MURINE MPN-MODELS

EHA Library, Yu-An Lin, 419098

T-cell engaging immunotherapy in early treatment of B-cell acute lymphoblastic leukemia (B-ALL)

EHA Library, Amgen, 4144088

How to Make the Most out of a Rapidly Evolving Treatment Landscape: Bispecific Antibodies in Relapsed Refractory Multiple Myeloma (RRMM)

EHA Library, Pfizer, 4144087

RESULTS FROM THE RANDOMIZED PHASE 3 DREAMM-8 STUDY OF BELANTAMAB MAFODOTIN PLUS POMALIDOMIDE AND DEXAMETHASONE VS POMALIDOMIDE PLUS BORTEZOMIB AND DEXAMETHASONE IN REPALPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Meletios Dimopoulos, 4136513

INTRA- AND EXTRACELLULAR PROTEOME DYNAMICS DURING NORMAL AND MALIGNANT HEMATOPOIETIC STEM CELL EXPANSION

EHA Library, Maria Jassinskaja, 4136514

ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED ECHO TRIAL

EHA Library, Michael L. Wang, 4136515

VITAMIN C SUPPLEMENTATION IN PATIENTS WITH CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE OR LOW-RISK MYELOID MALIGNANCIES: RESULTS FROM EVI-2, A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2 STUDY

EHA Library, Stine Ulrik Mikkelsen, 4136519

ELEVATED HEMOGLOBIN OF ANDEAN AYMARAS IS CAUSED BY ALTERNATIVELY SPLICED NFKB1

EHA Library, Josef Prchal, 4136518

ELA026 TARGETING OF SIRP(+) IMMUNE CELLS RESULTS IN A HIGH RESPONSE RATE AND IMPROVED 2-MONTH SURVIVAL OF TREATMENT-NAIVE MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PHASE 1 STUDY

EHA Library, Abhishek Maiti, 4136517

GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (GLOFIT-GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS OF A GLOBAL RANDOMIZED PHASE III TRIAL (STARGLO)

EHA Library, Jeremy Abramson, 4136516

Abstract Book 2024

EHA Library, Faculty / Presenters, 422826

Education Session on Pediatric acute myeloid leukemia (AML)

EHA Library, Faculty / Presenters, 402937

Education Session on Novel therapeutic approaches in acute myeloid leukemia (AML)

EHA Library, Faculty / Presenters, 402936

Education Session on Novel agents in multiple myeloma

EHA Library, Faculty / Presenters, 402933

Education Session on Inherited red blood cell disorders

EHA Library, Faculty / Presenters, 402932

Education Session on Hemochromatosis: From novel classification to treatment guidelines

EHA Library, Faculty / Presenters, 402929

Education Session on Hematopoietic stem cell biology and transplantation

EHA Library, Faculty / Presenters, 402928

Education Session on Genetics across all lymphoid malignancies

EHA Library, Faculty / Presenters, 402927

Education Session on Fetal-neonatal cytopenias: Focus on anemia

EHA Library, Faculty / Presenters, 402926

Education Sessions on Diffuse Large B-cell Lymphoma (DLBCL)

EHA Library, Faculty / Presenters, 402925

Education Session on What is hot in hemophilia?

EHA Library, Faculty / Presenters, 402944

Education Session on What's new in myeloproliferative neoplasms (MPN)?

EHA Library, Faculty / Presenters, 402945

Education Session on Myelodysplastic syndromes (MDS)

EHA Library, Faculty / Presenters, 402946

Education Session on Immunotherapy in indolent lymphomas

EHA Library, Faculty / Presenters, 402950

Education Sessions on CNS-involvement in acute lymphoblastic leukemia (ALL)

EHA Library, Faculty / Presenters, 402769

Education Sessions on Chronic myeloid leukemia (CML)

EHA Library, Faculty / Presenters, 402755

Education Session on Chronic lymphocytic leukemia (CLL)

EHA Library, Faculty / Presenters, 402754

Education session on Acute chest syndrome in sickle cell disease

EHA Library, Faculty / Presenters, 402753

Presidential Session II

EHA Library, Faculty / Presenters, 402752

Presidential Session I & Awards

EHA Library, Faculty / Presenters, 402751

Education Session on Acute acquired thrombosis and hemostasis challenges

EHA Library, Faculty / Presenters, 402750

HIGH COMPLETE RESPONSE RATE WITH TNB-486, A NOVEL CD19XCD3 T-CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY

EHA Library, Ryan Jacobs, 387924

IMPLICATIONS OF REGISTRY DATA FOR ACUTE MYELOID LEUKEMIA (AML) TREATMENT AND CARE DURING THE COVID-19 PANDEMIC

EHA Library, Bart Scott, 386418

PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA

EHA Library, Shaun Fleming, 386396

SURVIVAL OUTCOMES WITH CPX-351 VS 7+3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY

EHA Library, Jorge Cortes, 386346

CARDIOTOXICITY OF CPX-351 VS 7+3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA

EHA Library, Jorge Cortes, 386345

A REAL-WORLD EVALUATION OF TREATMENT PATTERNS AND OUTCOMES OF ACUTE MYELOID LEUKEMIA INDUCTION THERAPIES IN THE COMMUNITY SETTING

EHA Library, Keri Maher, 386344

A FIRST-IN-HUMAN STUDY OF CD123 NK CELL ENGAGER SAR443579 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH RISK-MYELODYSPLASIA

EHA Library, Anthony Selwyn Stein, 386323

FIVE-YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L-MIND STUDY

EHA Library, Johannes Duell, 385588

SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL

EHA Library, Tycel Phillips, 385544

PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT

EHA Library, Wojciech Jurczak, 385537

INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Francesca Palandri, 385512

LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES

EHA Library, Wojciech Jurczak, 386447

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3)

EHA Library, Meletios Dimopoulos, 387899

LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY

EHA Library, Uwe Platzbecker, 386522

TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN ROUTINE CLINICAL PRACTICE IN THE UNITED STATES

EHA Library, Sudipto Mukherjee, 386562

BASELINE AND EARLY POST-INFUSION BIOMARKERS ASSOCIATED WITH OPTIMAL RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL) IN THE KARMMA-3 STUDY OF TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA

EHA Library, Marc S. Raab, 386630

PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT):  IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS

EHA Library, Michel Delforge, 386734

PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY

EHA Library, Francesco Passamonti, 387868

EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY

EHA Library, Francesco Passamonti, 387867

LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY

EHA Library, Matteo Giovanni Della Porta, 387802

FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L-MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Johannes Duell, 387406

IMPACT OF TRANSFUSION BURDEN ON HEALTH-RELATED QUALITY OF LIFE AND FUNCTIONING IN PATIENTS WITH MYELOFIBROSIS: POST HOC ANALYSIS OF SIMPLIFY-1 AND -2

EHA Library, Ruben Mesa, 387290

EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Sagar Lonial, 387240

BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE

EHA Library, Michel Delforge, 387224

CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS

EHA Library, Guillermo Garcia-Manero, 387135

A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Guillermo Garcia-Manero, 387132

PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD) IN THE DREAMM-3 STUDY

EHA Library, Vania Hungria, 386793

BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS

EHA Library, Yi Lin, 386638

LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY

EHA Library, Thierry Facon, 386745

A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9

EHA Library, Saad Z. Usmani, 386693

RESULTS OF A PHASE 3 TRIAL OF AN ORAL CXCR4 ANTAGONIST, MAVORIXAFOR, FOR TREATMENT OF PATIENTS WITH WHIM SYNDROME

EHA Library, Jean Donadieu, 387880

SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS

EHA Library, Jan Bewersdorf, 385480

CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Nikhil Munshi, 387902

TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS

EHA Library, Nizar J Bahlis, 387892

PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Cyrille Touzeau, 387891

FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, María-Victoria Mateos, 387890

PATIENT PERSPECTIVES ON BCMA-TARGETED THERAPIES FOR MULTIPLE MYELOMA: A SURVEY CONDUCTED IN A PATIENT ADVOCACY GROUP

EHA Library, Jay R. Hydren, 386761

EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1

EHA Library, Niels W C J van de Donk, 386740

ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1

EHA Library, Leo Rasche, 386721

DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY

EHA Library, Manisha Bhutani, 386710

LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Surbhi Sidana, 386708

LONG-TERM REMISSION AND SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AFTER TREATMENT OF LCAR-B38M CAR-T – AT LEAST 5-YEAR FOLLOW-UP IN LEGEND-2

EHA Library, Jian‑Qing Mi, 386703

CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS

EHA Library, Nico Gagelmann, 385487

Abstract Book 2023

EHA Library, Faculty / Presenters, 400189

POVETACICEPT (ALPN-303), A POTENT DUAL BAFF/APRIL ANTAGONIST, FOR THE TREATMENT OF AUTOIMMUNE CYTOPENIAS AND OTHER ANTIBODY-RELATED DISEASES

EHA Library, Stacey Dillon, 387976

PUS1 REGULATES ERYTHROPOIESIS VIA TRNA PSEUDOURIDYLATION AND CYTOPLASMIC TRANSLATION

EHA Library, Yajing Chu, 387975

A NEW, EFFECTIVE, SAFE, NON-MYELOABLATIVE CONDITIONING REGIMEN WITH A HLA-MATCHED SIBLING DONOR FOR THE SEVERE SICKLE CELL PHENOTYPE IN ADULTS

EHA Library, Laure Joseph, 387974

LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL

EHA Library, Ali Taher, 387973

SAFETY AND EFFICACY OF RM-001 IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA: EARLY RESULTS FROM THE ONGOING OF AUTOLOGOUS HBG1/2 PROMOTER-MODIFIED CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS

EHA Library, Rongrong Liu, 387972

AN UPDATED FOLLOW-UP OF BRL-101, CRISPR-CAS9-MEDIATED GENE EDITING OF THE BCL11A ENHANCER FOR TRANSFUSION-DEPENDENT BETA-THALASSE

EHA Library, Biao Zheng, 387971

MALE PATIENTS WITH SCD HAVE A HIGHER RISK OF CEREBROVASCULAR DISEASE, INCREASED INFLAMMATORY MARKERS, AND POORER RESPONSE TO HYDROXYUREA

EHA Library, Margherita Di Mauro, 387969

INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)

EHA Library, Alan Anderson, 387968

PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY

EHA Library, Matthew Heeney, 387967

DIFFERENT MOLECULAR VASO-OCCLUSIVE TRIGGERS STIMULATE DISTINCT VASO-OCCLUSIVE PROFILES: IN VIVO RESULTS FROM MICE WITH SICKLE CELL ANEMIA

EHA Library, Lucas F. S. Gushiken, 387966

MATERNAL AND PERINATAL OUTCOMES OF SICKLE CELL DISEASE IN PREGNANCY: A NATIONWIDE STUDY IN FRANCE.

EHA Library, Laure Joseph, 387965

EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME

EHA Library, Rabi Hanna, 387964

TRANSFUSION INDEPENDENCE AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA

EHA Library, Franco Locatelli, 387970